Zydus launches anti-diabetic Dapagliflozin tablets in India

A once-daily oral treatment indicated as an adjunct to diet and exercise, Dapaglyn aims to improve glycemic control in adults with Type 2 diabetes mellitus.

Dapagliflozin is part of a newer class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. People who have diabetes can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Taking Dapagliflozin, alongwith lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking one's blood sugar may help patients manage their blood sugar levels and improve their health.

With diabetes becoming a major health burden in India which has a patient population of almost 77 million diabetics, it is critical to have therapies which are affordable and accessible to patients from all sections of society.

With Dapaglyn, a new generation of anti-diabetic therapy will now be accessible to a larger number of patients, thereby bringing in better compliance and improved disease management.

Read also: Zydus Cadila gets USFDA nod for multiple sclerosis drug

Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.